News

Hepatitis C Drug Development Advisory Group (HCV DrAG): An Overview

E-mail Print

The HCV Drug Development Advisory Group (DrAG) is a unique forum that brings together representatives from the U.S. and European regulatory agencies, academia, patient advocates and the pharmaceutical industry to build consensus around drug development-related issues. This Q&A video series features the reflections of several DrAG members on the impact the group has had on HCV drug development.

Read more »
 

Newsletters

E-mail Print
Past Newsletters
Read more »
 

In Memory of Dr. Koop

E-mail Print
koop-email
Read more »
 

In Memory of Dr. Koop

E-mail Print
koop-email
Read more »
 

HCV Drug Access for People with Bleeding Disorders

E-mail Print

OCT-17-11   The October 17, 2011 meeting entitled "HCV Drug Access for People with Bleeding Disorders" was the first in a series of meetings that will try and address issues associated with providing access to, if indicated, combination interferon-free experimental direct acting antivirals (DAAs).

The meeting was sponsored by the Forum, and was attended by representatives from regulatory agencies, academia, hemophilia treatment centers, non-profits associated with database management for those affected with bleeding and blood clotting disorders, community medical practitioners, patient advocates and pharmaceutical companies.

Read more »
 

HCV Trials in the Post-Approval Era of Telaprevir and Boceprevir - The Way Forward

E-mail Print

OCT-18-11 The October 18, 2011 meeting sponsored by the Forum was designed to facilitate consensus on issues with the choice of control arm in HCV trials and was attended by representatives from regulatory agencies (US, EMA, Health Canada), NIH, academia, pharmaceutical companies, and patient advocates. 

Read more »
 

Advancing HCV Drug Development: A Collaborative Approach

E-mail Print

DEC-06-10 A public meeting on HCV drug development was held Monday, December 6, 2010, in Washington, DC.

Read more »
 

HEP DART 2009, Frontiers in Drug Development for Viral Hepatitis Education Round-Table

E-mail Print
DEC-9-09 An education roundtable was held at the  HEP DART meeting in Hawaii On Tuesday, December 8, 2009  to educate Hepatitis C virus infected patients and update physicians who treat them about risk for, and avoidance of drug resistance to the next generation of HCV antiviral therapies.
Read more »
 

HCV DrAG Meeting#12

Print

The Forum for Collaborative HIV Research convened the 12th HCV Drug Development Advisory Group (DrAG) Meeting in London, UK in conjunction with the 49th annual meeting of the European Association for the Study of the Liver. The meeting was held on April 8, 2014 at the Grange City Hotel. 

Topics of discussion included:
1) Control Arms, Efficacy Standards and the Design of Future Clinical Trials
2)  Global HCV Access To Care

Meeting Materials and Links

Background Materials

Agenda 

Alavi et al. CID 2013. Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs inthe Opioid Substitution Setting: ETHOS Study.

Martin et al. CID 2013. Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy.

Presentations

Veronica Miller

Session 1: Control Arms, Efficacy Standards and the Design of Future Clinical Trials

Filip Josephson

Heiner Wedemeyer

Session 2: Global HCV Access To Care

Philippa Easterbrook

Charles Gore

Francisco  Averhoff 

Manal El-Sayed

Jason Grebely

Natasha Martin

Clifford Samuel 

 

 

 

 

 

 

 

HCV DrAG Meeting #11

E-mail Print

On November 5, 2013 the Forum for Collaborative HIV Research convened the 11th HCV Drug Development Advisory Group (DrAG) meeting in Washington, DC in conjunction with the 64th annual meeting of the American Association for the Study of Liver Diseases.

Read more »
 
Page 1 of 52